218 related articles for article (PubMed ID: 36880572)
1. Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients.
Lin RY; Anderson AD; Morris MI; Raja M; Komanduri KV; Camargo JF
Transpl Infect Dis; 2023 Apr; 25(2):e14043. PubMed ID: 36880572
[TBL] [Abstract][Full Text] [Related]
2. Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Kawamura K; Wada H; Nakasone H; Akahoshi Y; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Sato M; Tanihara A; Kimura SI; Kako S; Kanda Y
Transplant Cell Ther; 2021 May; 27(5):436.e1-436.e8. PubMed ID: 33775586
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
[TBL] [Abstract][Full Text] [Related]
4. Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.
Randi BA; Fernandes EG; Higashino HR; Lopes MH; Rocha VG; Costa SF; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2023; 65():e21. PubMed ID: 36946817
[TBL] [Abstract][Full Text] [Related]
5. Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age.
Saffar H; Mousavi SJ; Saffar H; Parsaei MR; Ghorbani GR; Saffar MJ
BMC Immunol; 2022 Jan; 23(1):2. PubMed ID: 35034609
[TBL] [Abstract][Full Text] [Related]
6. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K; Goa KL
Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
[TBL] [Abstract][Full Text] [Related]
7. Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis.
Wang M; Yuan Q; Deng PF; Fei Y; Zhang H; Zhou F; Chen WJ; Cao Q; Chen J; Gao YJ
World J Pediatr; 2023 Nov; 19(11):1062-1070. PubMed ID: 37087716
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Yoshida S; Fujii N; Kamoi C; Kitamura W; Fujiwara H; Asada N; Nishimori H; Fujii K; Matsuoka KI; Maeda Y
Acta Med Okayama; 2022 Jun; 76(3):247-253. PubMed ID: 35790354
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
10. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
11. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
12. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
13. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
[TBL] [Abstract][Full Text] [Related]
14. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
15. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
16. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation.
Bögeholz J; Russkamp NF; Wilk CM; Gourri E; Haralambieva E; Schanz U; Mueller NJ; Manz MG; Müller AMS
Biol Blood Marrow Transplant; 2020 Mar; 26(3):581-592. PubMed ID: 31682977
[TBL] [Abstract][Full Text] [Related]
18. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
[TBL] [Abstract][Full Text] [Related]
20. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
